# A Bioequivalence Study of Montelukast From Asmakast 10mg Tabs (Sandoz, Egypt) & Singulair 10mg Tabs (Merck)

> **NCT02480049** · PHASE1 · COMPLETED · sponsor: **Genuine Research Center, Egypt** · enrollment: 26 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Asmakast
- **DRUG:** Singulair

## Key facts

- **NCT ID:** NCT02480049
- **Lead sponsor:** Genuine Research Center, Egypt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2015-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02480049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02480049, "A Bioequivalence Study of Montelukast From Asmakast 10mg Tabs (Sandoz, Egypt) & Singulair 10mg Tabs (Merck)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02480049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*